Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Journal: The New England journal of medicine
Published: August 24, 2022
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 08, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Journal: The Lancet. Haematology
Published: July 27, 2020
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 01, 2020
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Journal: The Lancet. Haematology
Published: August 29, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Journal: The Lancet. Oncology
Published: October 18, 2017
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.
Journal: ACS medicinal chemistry letters
Published: May 23, 2017
Last Updated: 09/26/2026